Global Health & Medicine
Online ISSN : 2434-9194
Print ISSN : 2434-9186
Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration
Wataru MatsudaTatsuya OkamotoTatsuki UemuraKentaro KobayashiRyo SasakiAkio Kimura
Author information

2020 Volume 2 Issue 3 Pages 193-196


Severe COVID-19 is associated with a hyperinflammatory state, and corticosteroid therapy may be effective. We review the recent literature and discuss the appropriate dose and duration of corticosteroid therapy. Low-dose corticosteroid therapy is often used to treat COVID-19. However, several doses of methylprednisolone (or prednisolone) have been attempted, ranging from about 40 mg/day to 2 mg/kg/day. Doses may need to be adjusted depending on severity. Corticosteroid therapy is generally administered for a short period over several days. However, COVID-19-induced respiratory failure is often prolonged, so longer administration may be considered. Careful monitoring for complications due to corticosteroid therapy is vital.

Content from these authors
© 2020 National Center for Global Health and Medicine
Previous article Next article